Over 350 such drug candidates are being evaluated in the clinical stages of development, By Roots Analysis

Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.

 

To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html

 

• Eminent representatives from biopharmaceutical companies confirm the rising interest in the concept of subcutaneous drug delivery, highlighting some of the key drivers and upcoming trends in this domain
• More than 100 subcutaneous biologics have been approved and over 350 such drug candidates are being evaluated in the clinical stages of development, for the treatment of a wide variety of disease indications
• Antibodies and protein therapeutics represent the majority of subcutaneous biologics that are available / under investigation, designed for use against various therapeutic areas and having different dosing regimens
• Advances in drug delivery have led to the development of novel technology platforms, enabling the administration of highly viscous formulations, and supporting the development of subcutaneous dosage forms
• Several technology developers have out-licensed their proprietary platforms to pharmaceutical companies in order to enable them to develop subcutaneous formulations of their approved / pipeline products
• The increasing interest in this field is reflected in the yearly growth in partnership activity, including a number of licensing and product development deals related to subcutaneous formulations of various drug candidates
• There are several new and innovative drug delivery systems that facilitate subcutaneous administration; we identified over 300 such systems that are presently available / under development
• With several self-medication enabling devices, such as wearable injectors and autoinjectors, available in the market, developers are actively differentiating their offerings by incorporating advanced, patient-friendly features
• The market is anticipated to be worth over USD 180 billion in 2030; the projected opportunity is likely to be distributed across various types of molecules that are developed / being developed for different disease indications
• Pre-filled syringes continue to dominate the current market of subcutaneous drug delivery systems; technology developers are expected to continue relying on licensing agreements as their primary source of revenues333

 

The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:

• Phase of development

• Approved
• Pre-registration & Phase III
• Phase II & Phase II/III

 

• Type of molecule

• Cell and gene therapies
• Monoclonal antibodies
• Proteins
• Peptides (recombinant)
• Vaccines
• Others

 

• Target therapeutic area

• Autoimmune disorders
• Blood disorders
• Bone disorders
• Genetic disorders
• Metabolic disorders
• Neurological disorders
• Oncological disorders
• Respiratory disorders
• Others

 

• Type of drug delivery system
• Large volume wearable injectors
• Autoinjectors
• Prefilled syringes
• Needle-free injectors
• Drug reconstitution systems

 

• Revenues from licensing deals
• Upfront payments
• Milestone payments

 

• Key geographical regions
• North America
• Europe
• Asia Pacific
• Rest of the World

 

The Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:

• Adocia

• Ajinomoto Bio-Pharma Services
• Arecor
• Alteogen
• Ascendis Pharma
• Avadel Pharmaceuticals
• Camurus
• Creative BioMart
• Creative Biolabs
• DURECT
• Eagle Pharmaceuticals
• Halozyme Therapeutics
• MedinCell
• Xeris Pharmaceuticals
• Serina Therapeutics

 

Table of Contents

1. Preface

 

1. Executive Summary

 

1. Introduction

 

1. Subcutaneous Biologics: Current Market Landscape

 

1. Case Study: Leading Subcutaneous Biologics

 

1. Subcutaneous Formulation Technologies: Current Market Landscape

 

1. Subcutaneous Formulation Technology Developers: Company Competitiveness Analysis

 

1. Subcutaneous Formulation Technology Developers: Company Profiles

 

1. Partnerships and Collaborations

 

1. Subcutaneous Drug Delivery Systems: Current Market Landscape

 

1. Swot Analysis

 

1. Market Forecast and Opportunity Analysis

 

1. Concluding Remarks

 

1. Executive Insights

 

1. Appendix 1:  Tabulated Data

 

1. Appendix 2: List Of Companies And Organization

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

[email protected]